All the Drug Class Drugs
Interleukin Inhibitor. Secukinumab 150 mg. VIAL(pwdr. for sol. for inj.): 1×6ml.
PRE FILL. PEN/SYR (sol. for inj.): 1, 2×1ml Plaque psorias.: 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg. Psoriat. arthrit.: For pts. with concom. moder.-sev. plaque psorias. or who are anti-TNFα inadeq. responders (IR): 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg.
For other pts.: dose is 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by monthly mainten. dosing. Ankylos. spondylit.: 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing.
For all of the above indications, usually achieved within 16 wks. of tmt. Consider. should be given to discont. tmt. in pts. who have shown no response by 16 wks. of tmt. Some pts. with an init. partial response may subseq. improve with continued tmt. beyond 16 wks.
Plaque psorias.: Tmt. of moder.- sev. plaque psorias. in adult. who are candidates for system. ther.
Psoriat. arthrit.: Alone or in comb. with methotrexate (MTX): tmt. of active psoriat. arthrit. in adult pts. when the response to previous dis.-modif. anti-rheumatic drug (DMARD) ther. has been inadeq.
Ankylosing spondylitis: Tmt. of active ankylos. spondylitis in adult. who have responded inadeq. to convent. ther.
C/I: Severe hypersens. Clinical. important, active infec. (e.g. active tuberculosis).
Interleukin Inhibitor. Tildrakizumab 100 mg / 1 ml. PREFILL. SYRINGE:100 mg 100 mg SC inj. at wks. 0, and 4, every 12 wks. thereafter.
Tmt. of adult. with mod.-sev. plaque psoriasis who are candidates for syst. ther. or photother.
C/I: Hypersens. Clinic. import. active infect., e.g. active tubercul.
Interleukin Inhibitor. Ixekizumab 80 mg/ml. PRE FILL. PEN: 1.
160 mg by SC inject. (Two 80 mg inject.) at Week 0, follow. by 80 mg (1 injec.) at Weeks 2, 4, 6, 8, 10, and 12, then maint. dosing of 80 mg (1 inj.) every 4 wks. Consider. should be given to discount. tmt. in pts. who have shown no response after 16 -20 wks. of tmt. Some pts. with init. partial response may subseq. improve with contin. tmt. beyond 20 wks.
Tmy. of moder.-sev. plaque psoriasis in
adult. who are candidat. for system. ther.
C/I: Serious hypersens. Clinical. important active infec.
Interleukin Inhibitor. Ustekinumab 45 mg, 90 mg, 130 mg. PF syr: 1X 45/90 mg
VIAL: Sol. for SC inj.: 45 mg
VIAL: Concentr. for sol. for infus. :130 mg for IBD indicat. only
Init. dose of 45 mg SC, followed by 45 mg 4 weeks later, and then every 12 weeks. Discont. if no improvem. after 28 weeks. Ped. pop and IBD: See lit.
Plaque psor.: for moder. to sev. plaque psoriasis in adlts.(18 years or older) who failed to respond to, or who have a contraindic. to, or are intol. to other syst. ther. incl. ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A). Ped. plaque psoriasis: moder. to sev. plaque psoriasis in pts. from age of 6 years and older, who are inadeq. ctrolled by, or are intol. to, other syst. ther. or phototherapies. Psoriatic arthritis (PsA) alone or in combination with MTX: for tmt. of act. psoriatic arthritis in adlts when the resp. to prev. non-biological DMARD has been inadeq. Crohn’s Disease: adlts. with moder. to sev. act. Crohn’s dis. who had an inadeq. resp. with, lost resp. to, or were intol. to either convent. ther. or a TNFα antagonist or have contraindic. to such ther. Ulcerative colitis: adlts. with moder. to sev. act. UC who had an inadeq. resp. with, lost resp. to, or were intol. to either convent. ther. or a biologic or have contraindic. to such ther.
C/I: Hypersens. Clinic. important, act. infection.
